Cargando...

Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma

The expression of CD30 receptors is one of the defining characteristics of the malignant Reed-Sternberg cells of Hodgkin lymphoma. CD30 is rarely expressed by normal cells, and is rapidly internalized, making it an ideal therapeutic target for monoclonal antibodies and for antibody-drug conjugates (...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer J
Autores principales: Alperovich, Anna, Younes, Anas
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5042201/
https://ncbi.nlm.nih.gov/pubmed/26841013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000168
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!